-Pg. 2, Lines 39-45: Suggest adding "pharmacist" or "pharmacistprovided" to the keywords. -Pg. 4, Lines 23-24: Please clarify what is meant by "mixed evidence". -Pg. 4, Line 26: Please clarify who "we" are? Pharmacists? Society? -Pg. 4, Line 33-35: Please re-phrase this. I think what you're trying to say is that while there was a similar review done like what you're proposing, there have been a lot of legislative changes since then? -Methods and Analysis section: Not sure all of the information for why the JBI Reviewers Manual was developed is needed. Would like to see how this is similar to or different than the PRISMA-ScR. -Pg. 5, Lines 10-12: The steps you mention here and then explain with a header for each does not include "critical appraisal" which appears later as a subsection. Was this accidentally left out as a step? -Pg. 5, Lines 46-47: later (Line 6-7 on pg 6) it is mentioned that abortion services were excluded from review. Because of this I suggest removing this last sentence as it isn't related to the scope of this review.
-Objective: would add information that you had earlier to include "pharmacy-based initiatives for the feasibility, effectiveness and acceptability for preventing unintended pregnancy". -Pg. 7, Lines 37-41: The critical appraisal section talks about the "JBI Critical Appraisal Tools" but then doesn't explain these tools.
Not sure exactly what is needed here, but please provide more information to describe the appraisal tools. -Pg. 7, Lines 52-57: This paragraph doesn't quite make sense. Please re-phrase. I think what is trying to be said is that this review is part of a larger project with a goal of informing decisions on the practice of pharmacy in Australia?
VERSION 1 -AUTHOR RESPONSE
Reviewer 1: Dr. Alrasheedy Thank you for your positive feedback and interest in our scoping review.
Reviewer 2: Dr. Anderson 1. Are the methods described sufficiently to allow the study to be repeated? There is reference to "JBI Critical Appraisal Tools" but not enough information to explain how these tools apply to this review. Thank you for this constructive comment, we agree that more information should be included about the tools and how they will be used to extract information from the literature and influence the interpretation of the findings. The JBI have a series of critical appraisal tools targeted towards specific study designs. The critical appraisal tools each consist of a checklist and JBI encourage nuanced reporting of the findings of critical appraisal rather than ascribing a grade for evidence quality. We will conduct the appraisal at the time of data extraction and chart this evidence in the final report in tables and within the main text. We intend to present this information with the findings from the literature, to highlight new and developing areas in pharmacy practice requiring future research and high quality evidence to guide policy development and pharmacy practice. We have included this information in the revised manuscript (page 6, line 246-256).
2.
Objective: would add information that you had earlier to include "pharmacy-based initiatives for the feasibility, effectiveness and acceptability for preventing unintended pregnancy". We agree this will better align the objective with the research questions and have therefore made these changes to the manuscript (page 3, line 149-150).
3. Pg. 2, Lines 39-45: Suggest adding "pharmacist" or "pharmacist-provided" to the keywords.
Thank you for the keyword suggestions. As the keywords included in the manuscript are MeSH terms, we could not make the exact changes suggested. Instead we have removed "Delivery of Health Service" and replaced this with the MeSH terms "Community Pharmacy Services," and "Pharmacy." (Page 1, line 30-31)
Pg. 4, Lines 23-24:
Please clarify what is meant by "mixed evidence". "Mixed evidence" refers to the high variability in the literature pertaining to the feasibility, effectiveness and appropriateness of unintended pregnancy services offered in a community pharmacy setting. It is therefore difficult to determine what works, what's appropriate and what strategies can be adopted to address these issues. We have included this information in the revised manuscript (page 3, line 104-107).
Pg. 4, Line 26: Please clarify who "we" are? Pharmacists? Society?
Thank you for this query. "We" refers to researchers, policy makers and the groups responsible for the delivery of healthcare (clinicians, pharmacists, health care organisations). The findings of this review will be most relevant to these groups, as they may inform directions for future research and policy, in addition to the feasibility of services at the provider level. The manuscript has been updated to clarify the groups that we are referring to (page 3, line 108-109).
Pg. 4, Line 33-35: Please re-phrase this. I think what you're trying to say is that while there was a similar review done like what you're proposing, there have been a lot of legislative changes since then?
Thank you for the request to re-phrase these lines. We intended to say that a systematic review of pharmacy-based unintended pregnancy prevention initiatives was undertaken in the US related to policy and practice, prior to the advent of pharmacist-prescribed contraception legislation. Since this scope of practice expansion, a similar review has not been undertaken in the US or internationally. (page 3, line 116-120)
Methods and Analysis section: Not sure all of the information for why the JBI Reviewers
Manual was developed is needed. Would like to see how this is similar to or different than the PRISMA-ScR. Thank you for requesting this clarification. We agree with the suggestion to clarify the difference between the JBI manual and PRISMA-ScR and how they will be used for the review. We chose to use the two guidelines as they inform different aspects of the methodology. The JBI handbook provides a comprehensive methodological framework on the conduct of scoping reviews, while PRISMA-ScR provides guidelines for best-practice reporting, however does not provide detailed guidance on methodological conduct. We have removed the additional information about the Joanna Briggs Institute and the development of the Reviewer's Manual, and have re-worked the section to be clearer about the use of the different guidelines. Additionally, we highlight the relevance of the JBI Scoping Review methodology to the review outcomes, to demonstrate congruence with the objectives and methodology and justify why the methodological approach was chosen. (Page 3-4, line 133-147) 8. Pg. 5, Lines 10-12: The steps you mention here and then explain with a header for each does not include "critical appraisal" which appears later as a subsection. Was this accidentally left out as a step?
Thank you for bringing this to our attention. We initially did not intend on critically appraising the literature as this is not typically common practice for scoping reviews. The JBI handbook does not include this as a separate step in the conduct of scoping reviews. We have highlighted that we will also be undertaking a critical appraisal of the literature in this paragraph. (page 4, line 146) 9. Pg. 5, Lines 46-47: later (Line 6-7 on pg 6) it is mentioned that abortion services were excluded from review. Because of this I suggest removing this last sentence as it isn't related to the scope of this review. Thank you for this comment. We agree that the mention of abortion services is not within scope for this review and have removed this sentence as suggested (page 4, line 174) 10. Pg. 7, Lines 37-41: The critical appraisal section talks about the "JBI Critical Appraisal Tools" but then doesn't explain these tools. Not sure exactly what is needed here, but please provide more information to describe the appraisal tools.
Thank you for this constructive comment. Our response to this comment has been addressed under Comment 1. We have included more detailed information about the critical appraisal tools and the way in which they will be used in the revised manuscript (page 6, line 246-256).
Pg. 7, Lines 52-57: This paragraph doesn't quite make sense. Please re-phrase. I think what is trying to be said is that this review is part of a larger project with a goal of informing decisions on the practice of pharmacy in Australia?
Thank you for bringing this to our attention. The scoping review is part of a larger project with a goal of informing the feasibility of contraceptive decision aids for their potential use in primary care settings within Australia, to enhance comprehensive contraceptive counselling. The paragraph has been rephrased to improve readability in the revised manuscript (page 7, line 265-268)
Additional changes to the manuscript to improve formatting, clarity and readability are: Once again, thank you for considering our manuscript for publishing in BMJ Open. We look forward to hearing the outcome of the submission soon. 
GENERAL COMMENTS
Nice job on the revisions, and addressing all of my suggested edits and clarifications. This draft is more concise and much easier to read. I look forward to reading about the results of your review!
